These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 56310)

  • 21. [Isolation and characteristics of the "direct" hemolytic factor in the venom of the Central Asian cobra].
    Iukel'son LIa; Sadykov E; Sorokin VM
    Biokhimiia; 1974; 39(4):816-21. PubMed ID: 4441571
    [No Abstract]   [Full Text] [Related]  

  • 22. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.
    Ballow M; Cochrane CG
    J Immunol; 1969 Nov; 103(5):944-52. PubMed ID: 4981797
    [No Abstract]   [Full Text] [Related]  

  • 23. Studies in vivo of cobra factor and murine C3.
    Pepys MB
    Immunology; 1975 Feb; 28(2):369-77. PubMed ID: 804439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody plaque-forming cells in mice immunized with human gamma globulin. I. Technical considerations.
    Hege JS; Epstein WV
    J Immunol; 1971 Mar; 106(3):786-92. PubMed ID: 4100694
    [No Abstract]   [Full Text] [Related]  

  • 25. Strong interaction of lipopolysaccharides possessing the mannose homopolysaccharides with complement and its relation to adjuvant action.
    Yokochi T; Inoue Y; Kimura Y; Kato N
    J Immunol; 1990 Apr; 144(8):3106-10. PubMed ID: 2182713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo decomplementation of guinea pigs with cobra venom factor and anti-C3 serum: analysis of the requirement of C3 and C5 for the mediation of endotoxin-induced death.
    Drake WP; Pokorney DR; Kopyta LP; Mardiney MR
    Biomedicine; 1976 May; 25(3):91-4. PubMed ID: 949521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
    Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
    Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. II. Physico-chemical characterization of the activated complex.
    Miyama A; Kato T; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):205-14. PubMed ID: 1218075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies of the alternate pathway in chelated serum.
    Forsgren A; Mclean RH; Michael AF; Quie PG
    J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anticomplementary activity of a polyanion: pentosan-poly-sulfoester, II.--Mode of action and "in vitro " inhibition of human complement hemolytic activity (author's transl)].
    Berthoux FX; Freyria AM; Traeger J
    Pathol Biol (Paris); 1977 Feb; 25(2):105-8. PubMed ID: 322041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A.
    Pepys MB; Tompkins C; Smith AD
    J Immunol Methods; 1979; 30(2):105-17. PubMed ID: 574149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoglobulin classes of antibody-forming cells in mice. 3. Immunoglobulin antibody restriction of plaque-forming cells demonstrated by the double immunofluorescent technique.
    Cosenza H; Nordin AA
    J Immunol; 1970 Apr; 104(4):976-83. PubMed ID: 4191865
    [No Abstract]   [Full Text] [Related]  

  • 34. Isolation and characterization of a low molecular weight complement inhibitor present in normal human serum.
    Baker PJ; Osofsky SG
    Clin Exp Immunol; 1981 Mar; 43(3):549-56. PubMed ID: 6912799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation.
    Goslings WR; Prodeus AP; Streilein JW; Carroll MC; Jager MJ; Taylor AW
    Invest Ophthalmol Vis Sci; 1998 May; 39(6):989-95. PubMed ID: 9579478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppression by cobra factor: distribution, antigen-induced blast transformation and trapping of lymphocytes during in vivo complement depletion.
    Pepys MB; Mirjah DD; Dash AC; Wansbrough-Jones MH
    Cell Immunol; 1976 Feb; 21(2):327-36. PubMed ID: 1260864
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemolytic plaque formation by mouse spleen cells producing antibodies against rabbit immunoglobulin G.
    Segre M; Segre D
    J Immunol; 1967 Nov; 99(5):867-75. PubMed ID: 4169034
    [No Abstract]   [Full Text] [Related]  

  • 38. Dietary stimulation of immune mechanisms.
    Wostmann BS; Pleasants JR; Bealmear P
    Fed Proc; 1971; 30(6):1779-84. PubMed ID: 4108130
    [No Abstract]   [Full Text] [Related]  

  • 39. The immunologic properties of free endotoxin of Shigella sonnei.
    Kowalewska D; Romanowska E; Slopek S; Mulczyk M
    Arch Immunol Ther Exp (Warsz); 1970; 18(6):617-29. PubMed ID: 4923971
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunization in vitro of mouse spleen cells in different cultural conditions.
    Bernardini A; Messina A
    G Batteriol Virol Immunol Ann Osp Maria Vittor Torino; 1971; 64(5):123-35. PubMed ID: 4113469
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.